

The Manager
Companies Announcement Platform
SIM Venture Securities Exchange

9 February 2012

4-Fold Mould Produces Another Batch of SoloFlow®

HIGHLIGHTS:

- **28,600 SoloFlow® cannula already shipped to SII for first commercial order**
 - **25,000 additional SoloFlow® cannula produced from 4-fold mould**
-

Telezon Limited® ("the Company") is pleased to announce that its' *4-fold pre-production mould* ("tool") has successfully produced 25,000 SoloFlow® Medical Transfer Cannulae. This is in addition to 28,600 needles delivered to Serum Institute of India ("SII") on 30 January 2012.

The *pre-production mould* successfully produced 25,000 needles in a continuous, extended-period production run. Precise refinements of the tool continue to be made thereby enhancing its immediate and future capabilities.

Since shipment of the first commercial batch (28,600 needles), the Company has maximised production times and made advancements to the CoreIT® Technology in preparation for larger production volumes. A larger capacity production tool will allow the Company to produce greater volumes of needles, while capitalising on commercial efficiencies (such as time and cost).

This *4-fold pre-production mould* enables:

- more needles produced with greater time and cost efficiency – capacity of up to **5 million units a year**
- a stable production process
- the demonstration of *CoreIT®* technology to prospective commercial partners.

Please refer to our website for more detailed information on our products.

Telezon is listed on SIM Venture Securities Exchange [www.simvse.com.au] (SIM: TLZ).

For and on behalf of Telezon Limited,

Dr Michelle Carr
Director & Co.Secretary
T: 61 03 9763 8605
F: 61 03 9763 2714